Attenuated Multivalent Mopevac Vaccine for New World Arenavirus Protection

The patent creates a universal vaccine platform using a single attenuated Mopeia virus backbone that can express heterologous glycoprotein precursors from multiple different arenaviruses. This allows one vaccine formulation to provide protection against multiple virus species (Junin, Machupo, Guanarito, Sabia, Chapare) simultaneously, eliminating the need to develop separate vaccines for each arenavirus while maintaining specific protective efficacy against each target virus.

The patent merges multiple viral antigen components into a single recombinant virus vector. The Mopeia virus backbone is engineered to carry and express glycoprotein precursor genes from multiple different arenaviruses, combining what would traditionally require multiple separate vaccine formulations into one integrated immunogenic composition that elicits cross-protective immune responses.

The patent employs a highly attenuated Mopeia virus backbone with multiple attenuating mutations that severely limit its replicative capacity and pathogenicity. This 'weakened' viral platform can still effectively deliver and express heterologous arenavirus glycoproteins to induce protective immunity, but its attenuated state prevents it from causing severe disease or adverse immune enhancement effects, making it safer than using wild-type or less-attenuated virus-based multivalent vaccines.

The attenuated Mopeia virus serves as a safe intermediary delivery vehicle that carries and expresses the pathogenic arenavirus glycoprotein antigens without itself causing severe disease. This intermediary approach allows the immune system to be exposed to the protective antigens of multiple arenaviruses through a benign viral vector, avoiding the risks associated with using the actual pathogenic viruses or less-safe vaccine platforms.